Daunorubicin Hydrochloride
- Atc Codes:L01DB02
- CAS Codes:23541-50-6#20830-81-3
- PHARMGKB ID:23541-50-6#20830-81-3
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Daunoblastin, Daunoxome; Belgium: Cerubidine; Denmark: Cerubidin, Daunoxome; Finland: Daunoxome; France: Cerubidine; Germany: Daunoblastin, Daunoxome; Greece: Cerubidine, Daunoblastin, Daunoblastina, Daunoxome; Hungary: Daunoblastina; Ireland: Cerubidin, Daunoxome; Italy: Daunoblastina; Luxembourg: Cerubidine, DaunoXome; Netherlands: Cerubidine, DaunoXome; Portugal: Daunoxome; Romania: Daunoblastina; Slovakia: Daunoblastina; Spain: Daunoblastina; Sweden: Cerubidin, Daunoxome; UK: Daunorubicin.
North America
Canada: Cerubidine, Daunorubicin; USA: Cerubidine, Daunorubicin.
Latin America
Argentina: Daunoblastina, Daunorubicina, Maxidauno; Brazil: Daunoblastina; Mexico: Daunorubicina, Rubilem.
Asia
Japan: Daunomycin.
Drug combinations
Daunorubicin Hydrochloride and Cytarabine
Daunorubicin Hydrochloride, Cytarabine, and Etoposide
Chemistry
Daunorubicin Hydrochloride: C~27~H~29~NO~10~ HCl. Mw: 563.98. (1) 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride; (2)(1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside hydrochloride. CAS-23541-50-6; CAS-20830-81-3 (daunorubicin)(1976).
Pharmacologic Category
Antineoplastic Agents; Cytotoxic Antibiotics and Related Substances. Anthracycline Agent. Topoisomerase II Inhibitor. (ATC-Code: L01DB02).
Mechanism of action
Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs and by steric obstruction. It appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA.
Therapeutic use
Treatment of acute lymphocytic and nonlymphocytic leukemias.
Pregnancy and lactiation implications
May cause fetal harm. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to daunorubicin or any component of the formulation.
Warnings and precautions
May cause bone marrow suppression or dose-related myocardial toxicity. Secondary leukemias may occur with combination chemotherapy or radiation therapy. Caution in patients who have received radiation therapy. Potent vesicant, only for I.V. administration. Caution in hepatic or renal impairment.